A human monoclonal antibody neutralizing SARS-CoV-2 Omicron variants containing the L452R mutation
Journal of Virology · 2024
DOI: 10.1128/jvi.01223-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Virology, 2024. Verfasst von Saskia C Stein und 25 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Virology, Hannover Medical School, Hannover, Germany. Hauptthemen laut MEDLINE: SARS-CoV-2, Antibodies, Neutralizing, COVID-19, Spike Glycoprotein, Coronavirus. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: State Lower-Saxony, Ministry of Science and Culture of Lower Saxony, German Federal Ministry of Education and Science (BMBF).
Abstract (Originalsprache)
The effectiveness of SARS-CoV-2 therapeutic antibodies targeting the spike (S) receptor-binding domain (RBD) has been hampered by the emergence of variants of concern (VOCs), which have acquired mutations to escape neutralizing antibodies (nAbs). These mutations are not evenly distributed on the RBD surface but cluster on several distinct surfaces, suggesting an influence of the targeted epitope on the capacity to neutralize a broad range of VOCs. Here, we identified a potent nAb from convalescent patients targeting the receptor-binding domain of a broad range of SARS-CoV-2 VOCs. Except for the Lambda and BA.2.86 variants, this nAb efficiently inhibited the entry of most tested VOCs, including Omicron subvariants BA.1, BA.2, XBB.1.5, and EG.5.1 and to a limited extent also BA.4/5, BA.4.6, and BQ.1.1. It bound recombinant S protein with picomolar affinity, reduced the viral load in the lung of infected hamsters, and prevented the severe lung pathology typical for SARS-CoV-2 infections. An X-ray structure of the nAb-RBD complex revealed an epitope that does not fall into any of the conventional classes and provided insights into its broad neutralization properties. Our findings highlight a conserved epitope within the SARS-CoV-2 RBD that should be preferably targeted by therapeutic antibodies and inform rational vaccine development. IMPORTANCE Therapeutic antibodies are effective in preventing severe disease from SARS-CoV-2 infection and constitute an important option in pandemic preparedness, but mutations within the S protein of virus variants (e.g., a mutation of L452) confer resistance to many of such antibodies. Here, we identify a human antibody targeting the S protein receptor-binding domain (RBD) with an elevated escape barrier and characterize its interaction with the RBD functionally and structurally at the atomic level. A direct comparison with reported antibodies targeting the same epitope illustrates important differences in the interface, providing insights into the breadth of antibody binding. These findings highlight the relevance of an extended neutralization profiling in combination with biochemical and structural characterization of the antibody-RBD interaction for the selection of future therapeutic antibodies, which may accelerate the control of potential future pandemics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Virology, Hannover Medical School, Hannover, Germany.
- Institute of Biochemistry, Center of Structural and Cell Biology in Medicine, University of Lübeck, Lübeck, Germany.
- Laboratory of Experimental Immunology, Institute of Virology, University of Cologne, Cologne, Germany.
- Institute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, Hannover, Germany.
- German Primate Center, Leibniz Institute for Primate Research, and Faculty of Biology and Psychology, University Göttingen, Göttingen, Germany.
- German Center for Infection Research, Partner Site Bonn-Cologne, Cologne, Germany.
ORCID-Profile: Guido Hansen, Florian Klein, Thomas F Schulz, Thomas Krey
Förderung
- State Lower-Saxony
- Ministry of Science and Culture of Lower Saxony
- German Federal Ministry of Education and Science (BMBF)
- German Research Foundation
Zitieren
APA
Stein, S. C., Hansen, G., Ssebyatika, G., Ströh, L. J., Ochulor, O., Herold, E., Schwarzloh, B., Mutschall, D., Zischke, J., Cordes, A. K., Schneider, T., Hinrichs, I., Blasczyk, R., Kleine-Weber, H., Hoffmann, M., Klein, F., Kaiser, F. K., Gonzalez-Hernandez, M., Armando, F., …, & Krey, T. (2024). A human monoclonal antibody neutralizing SARS-CoV-2 Omicron variants containing the L452R mutation. Journal of Virology. https://doi.org/10.1128/jvi.01223-24
Vancouver
Stein SC, Hansen G, Ssebyatika G, Ströh LJ, Ochulor O, Herold E, et al. A human monoclonal antibody neutralizing SARS-CoV-2 Omicron variants containing the L452R mutation. Journal of Virology. 2024. doi:10.1128/jvi.01223-24
BibTeX
@article{Stein2024,
author = {Stein, Saskia C and Hansen, Guido and Ssebyatika, George and Ströh, Luisa J and Ochulor, Okechukwu and Herold, Elisabeth and Schwarzloh, Britta and Mutschall, Doris and Zischke, Jasmin and Cordes, Anne K and Schneider, Talia and Hinrichs, Imke and Blasczyk, Rainer and Kleine-Weber, Hannah and Hoffmann, Markus and Klein, Florian and Kaiser, Franziska K and Gonzalez-Hernandez, Mariana and Armando, Federico and Ciurkiewicz, Malgorzata and Beythien, Georg and Pöhlmann, Stefan and Baumgärtner, Wolfgang and Osterhaus, Albert and Schulz, Thomas F and Krey, Thomas},
title = {A human monoclonal antibody neutralizing SARS-CoV-2 Omicron variants containing the L452R mutation},
journal = {Journal of Virology},
year = {2024},
doi = {10.1128/jvi.01223-24}
}
EUVIMED